Adaptimmune Launches Tecelra Amid Strong Q2 Results
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
- Latest
- Trending
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
Explore if Alphabet stock remains a buy as it faces legal action. Understand the implications for investors.
Explore how AI can support retirement planning and the limitations it currently faces in personalized financial advice.
Stock market sees gains as inflation slows, hinting at possible Fed rate cuts. Key companies in focus include Intel and ...
David Salvagnini leads NASA's AI advancements, ensuring ethical and cutting-edge technology for space and Earth missions.
MITRE's new initiative, Defending OT with ATT&CK, strengthens security for critical infrastructure by detailing adversarial techniques.
Orora declines Lone Star's $2.25B bid, citing undervaluation. Offer was 33.9% premium to last stock close.
Experts discuss 'oversold' markets and strategies to navigate upcoming stock turbulence amid economic volatility.
India's trade deficit in July hit $23.5 billion, driven by weak exports, raising concerns over global economic resilience.
BofA clients net buy US stocks, first in 5 weeks, amid recession fears driving sharp market sell-offs.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.